Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression
by
Andreoli V, Caillard V, Deo RS, Rybakowski JK, Versiani M.
Primario Servizi Psychiatri, Ospedale di Soave, Soave, Italy.
andreoliv@easyasp.it
Clin Psychopharmacol 2002 Aug;22(4):393-9


ABSTRACT

The clinical profile of reboxetine, a selective noradrenaline reuptake inhibitor, was compared with that of the selective serotonin reuptake inhibitor fluoxetine and placebo in a double-blind, multicenter, parallel-group clinical trial of patients with major depression. Among the 381 patients treated with reboxetine 8 to 10 mg/day, fluoxetine 20 to 40 mg/day, or placebo for up to 8 weeks, a statistically significant greater reduction in the mean Hamilton Rating Scale for Depression (21-item HAM-D) total score (the primary efficacy variable) was seen for both active treatment groups compared with placebo (p < 0.024). A significantly greater proportion of patients treated with either reboxetine or fluoxetine also achieved a response (>or=50% reduction in HAM-D) or remission (HAM-D
Selectivity
Reboxetine
NARIs v SSRIs
Switching from Prozac
Reboxetine: product info
Noradrenergic antidepressants
Noradrenaline and cerebral aging
Reboxtine versus fluoxetine (Prozac)



Refs
and further reading

HOME
HedWeb
Nootropics
erythroxylum-coca.com
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family